Аннотация
В 1984 г. датские дерматологи описали кожные высыпания, ограниченные ягодицами с возможным вовлечением интертригинозных зон и сгибательных областей, и назвали этот паттерн «синдром бабуина». В начале ХХI в. швейцарскими дерматологами была предложена новая аббревиатура SDRIFE (симметричная интертригинальная и изгибная экзантема, связанная с лекарственными средствами) вместе с пятью характерными диагностическими критериями. Мы провели поиск в базе данных PubMed по ключевым терминам: «baboon syndrome», «symmetrical drug-related intertriginous and flexural exanthema», «SDRIFE» с момента первой публикации (1984 г.) по 30.04.2023. Найдено 120 описаний синдрома бабуина или SDRIFE, который несколько чаще встречался у мужчин. Отмечено увеличение частоты развития с возрастом, 60% случаев приходилось на пациентов старше 50 лет. Географически более половины (52,4%) случаев зарегистрированы в Европе, преимущественно в южноевропейских и западноевропейских странах, 20% – в Индии и 16,2% – в азиатских странах. Обращает на себя внимание многообразие лекарственных препаратов, которые могут быть причиной развития синдрома бабуина/SDRIFE. Почти половина – 59 (49,2%) случаев из 120 представленных в обзоре, связаны с антибиотиками, 24 (20%) случая – с антибиотиками группы пенициллина. В период пандемии новой коронавирусной инфекции были описаны случаи развития SDRIFE у больных COVID-19 и после вакцинации от COVID-19. Ведущее место в диагностике и лечении SDRIFE принадлежит дерматологу. Однако с учетом многообразия препаратов-виновников с SDRIFE может столкнуться в своей практике врач любой специальности.
Ключевые слова: синдром бабуина, симметричная интертригинальная и изгибная экзантема, связанная с лекарственными средствами, синдром SDRIFE, лекарственные препараты, препараты-виновники, эпидемиология
Об авторе
Д.И. Трухан
ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России, Омск, Россия
dmitry_trukhan@mail.ru
Список литературы
1. Andersen KE, Hjorth N, Menné T. The baboon syndrome: systemicallyinduced allergic contact dermatitis. Contact Dermatitis 1984; 10 (2): 97–100. DOI: 10.1111/j.1600-0536.1984.tb00343.x
2. Häusermann P, Harr T, Bircher AJ. Baboon syndrome resulting from systemic drugs: is there strife between SDRIFE and allergic contact dermatitis syndrome? Contact Dermatitis 2004; 51 (5–6): 297–310. DOI: 10.1111/j.0105-1873.2004.00445.x
3. Winnicki M, Shear NH. A systematic approach to systemic contact dermatitis and symmetric drug-related intertriginous and flexural exanthema (SDRIFE): a closer look at these conditions and an approach to intertriginous eruptions. Am J Clin Dermatol 2011; 12 (3): 171–80. DOI: 10.2165/11539080-000000000-00000
4. Cabrera Hernandez V, Gonzalez Afonso M, Callero Viera A, Martin-Fernandez Martin L. Symmetrical drug-related intertriginous and flexural exanthema due to clindamycin. BMJ Case Rep 2019; 12 (8): e230077. DOI: 10.1136/bcr-2019-230077
5. de Risi-Pugliese T, Barailler H, Hamelin A et al. Symmetrical drug-related intertriginous and flexural exanthema: A little-known drug allergy. J Allergy Clin Immunol Pract 2020; 8 (9): 3185–9.e4. DOI: 10.1016/j.jaip.2020.04.052
6. Wolf R, Tüzün Y. Baboon syndrome and toxic erythema of chemotherapy: Fold (intertriginous) dermatoses. Clin Dermatol 2015; 33 (4): 462–5. DOI: 10.1016/j.clindermatol.2015.04.008
7. Harbaoui S, Litaiem N. Symmetrical Drug-related Intertriginous and Flexural Exanthema.2022 Oct 3. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. URL: https://pubmed.ncbi. nlm.nih.gov/30969572/
8. Tan SC, Tan JW. Symmetrical drug-related intertriginous and flexural exanthema. Symmetrical drug-related intertriginous and flexural exanthema. Curr Opin Allergy Clin Immunol 2011; 11 (4): 313–8. DOI: 10.1097/ACI.0b013e3283489d5f
9. Muresan AM, Metze D, Böer-Auer A, Braun SA. Histopathological Spectrum and Immunophenotypic Characterization of Symmetrical Drug-Related Intertriginous and Flexural Exanthema. Am J Dermatopathol 2021; 43 (2): 103–11. DOI: 10.1097/DAD. 0000000000001722
10. Schuler AM, Smith EH, Chaudet KM et al. Symmetric drug-related intertriginous and flexural exanthema: Clinicopathologic study of 19 cases and review of literature. J Cutan Pathol 2021; 48 (12): 1471–9. DOI: 10.1111/cup.14090
11. Karadag AS, Ozlu E, Akdeniz N et al. Oral mucosal involvement and petechial lesions: a SDRIFE case with unusual findings. Cutan Ocul Toxicol 2016; 35 (2): 157–9. DOI: 10.3109/15569527.2015.1067227
12. Özkaya E, Babuna G. A challenging case: Symmetrical drug related intertriginous and flexural exanthem, fixed drug eruption, or both? Pediatr Dermatol 2011; 28 (6): 711–4. DOI: 10.1111/j.1525-1470. 2011.01656.x
13. Lima Miranda O, Martins J, Almeida A et al. Symmetrical Drug-related Intertriginous and Flexural Exanthema (Baboon Syndrome). Eur J Case Rep Intern Med 2021; 8 (12): 003029. DOI: 10.12890/ 2021_003029
14. Cancela-Díez B, López-Delgado D, Aneiros-Fernandez J, RuizVillaverde R. A Case of Intertriginous and Flexural Exanthema caused by Amoxicillin. Sultan Qaboos Univ Med J 2019; 19 (4): e369-e371. DOI: 10.18295/squmj.2019.19.04.014
15. Alpagat G, Baccioglu A, Dumanoglu B et al. Amoxicillin/Clavulanic Acid-Induced Symmetric Drug-Related Intertrigious and Flexural Exanthema. Cureus 2023; 15 (1): e33849. DOI: 10.7759/cureus.33849
16. Dogru M, Ozmen S, Ginis T et al. Symmetrical drug-related intertriginous and flexural exanthema (baboon syndrome) induced by amoxicillin-clavulanate. Pediatr Dermatol 2012; 29 (6): 770–1. DOI: 10.1111/j.1525-1470.2011.01577.x
17. Cox JAG. Symmetric, itching exanthema of the skin folds after penicillin use. Ned Tijdschr Geneeskd 2023 Jan 4; 167: D7005. URL: https://pubmed.ncbi.nlm.nih.gov/36633087/
18. Blackmur JP, Lammy S, Baring DE. Baboon syndrome: an unusual complication arising from antibiotic treatment of tonsillitis and review of the literature. BMJ Case Rep 2013; 2013: bcr2013201977. DOI: 10.1136/bcr-2013-201977
19. Handisurya A, Stingl G, Wöhrl S. SDRIFE (baboon syndrome) induced by penicillin. Clin Exp Dermatol 2009; 34 (3): 355–7. DOI: 10.1111/j.1365-2230.2008.02911.x
20. Chong WS, Lim HL. Symmetrical drug-related intertriginous and flexural exanthema (baboon syndrome) with fever induced by oral cloxacillin: does fever confound the diagnosis? J Dermatol 2010; 37 (9): 830–2. DOI: 10.1111/j.1346-8138.2010.00890.x
21. Heck J, Stichtenoth DO, Mettin R et al. Remdesivir-induced symmetrical drug-related intertriginous and flexural exanthema (SDRIFE)? A case report with review of the literature. Eur J Clin Pharmacol 2021; 77 (1): 141–4. DOI: 10.1007/s00228-020-02955-4
22. Magnolo N, Metze D, Ständer S. Pustulobullous variant of SDRIFE (symmetrical drug-related intertriginous and flexural exanthema). J Dtsch Dermatol Ges 2017; 15 (6): 657–9. DOI: 10.1111/ddg.13031
23. Blanco Garcia-Granero D, Barranco R, García-Moguel I et al. First Case of Symmetric Drug-Related Intertriginous and Flexural Exanthema Induced by Meropenem. J Investig Allergol Clin Immunol 2021; 31 (6): 516-–7. DOI: 10.18176/jiaci.0685
24. Favrelière S, Hosteing S, Jazeron JF et al. A case of fixed drug eruption induced by doxycycline, mimicking a symmetrical drug-related intertriginous and flexural exanthema (SDRIFE). Therapie 2020t; 75 (5): 511–3. DOI: 10.1016/j.therap.2019.10.002
25. Li DG, Thomas C, Weintraub GS, Mostaghimi A. Symmetrical Drug-related Intertriginous and Flexural Exanthema Induced by Doxycycline. Cureus 2017; 9 (11): e1836. DOI: 10.7759/cureus.1836
26. Sahu K, Sirka CS, Pradhan S, Rout AN. Co-occurrence of Symmetrical Drug-Related Intertriginous and Flexural Exanthema (SDRIFE) and Pigmented Fixed Drug Eruption (FDE) in a Single Patient Due to Doxycycline: A Case Report. Indian Dermatol Online J 2020; 11 (1): 62–4. DOI: 10.4103/idoj.IDOJ_104_19
27. Bumbacea RS, Ali S, Ogneva DO et al. Drug Provocation Testing in the Diagnosis of Symmetrical Drug-Related Intertriginous and Flexural Exanthema (SDRIFE) Induced by Clarithromycin. Maedica (Bucur) 2021; 16 (2): 297–301. DOI: 10.26574/maedica.2020.16.2.297
28. Moreira C, Cruz MJ, Cunha AP, Azevedo F. Symmetrical drug-related intertriginous and flexural exanthema induced by clarithromycin. An Bras Dermatol 2017; 92 (4): 587–8. DOI: 10.1590/abd1806-4841. 20176125
29. Goossens C, Sass U, Song M. Baboon syndrome. Dermatology 1997; 194 (4): 421–2. DOI: 10.1159/000246167
30. Nespoulous L, Matei I, Charissoux A et al. Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) associated with pristinamycin, secnidazole, and nefopam, with a review of the literature. Contact Dermatitis 2018; 79 (6): 378–80. DOI: 10.1111/cod. 13084
31. Tsai YW, Chung WH, Wang CW, Cheng CY. Levofloxacin-induced symmetric drug-related intertriginous and flexural exanthema. Contact Dermatitis 2022; 86 (1): 64–6. DOI: 10.1111/cod.13979
32. Megna M, Camela E, Ocampo Garza SS et al. Ciprofloxacin-induced symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) in a psoriasis patient. Contact Dermatitis 2021; 85 (4): 467– 9. DOI: 10.1111/cod.13882
33. Kothari R, Mannu A, Vashisht D et al. Vancomycin Associated Purpuric Symmetrical Drug-Related Intertriginous and Flexural Exanthema: A Rare Association and an Uncommon Presentation. J Clin Pharmacol 2022; 62 (10): 1325–7. DOI: 10.1002/jcph.2069
34. Culav I, Ljubojevic S, Buzina DS. Baboon syndrome/SDRIFE due to sulfamethoxazole-trimethoprim. Int J Dermatol 2013; 52 (9): 1159–60. DOI: 10.1111/j.1365-4632.2011.05107.x
35. Şikar Aktürk A, Bayramgürler D, Salman S et al. Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) induced by oral metronidazole. Cutan Ocul Toxicol 2014; 33 (4): 337–8. DOI: 10.3109/15569527.2013.823981
36. Kumagai J, Nakamura A, Ogawa S, Washio K. Intravaginal metronidazole ovule-related allergic contact dermatitis. Contact Dermatitis 2021; 85 (1): 85–6. DOI: 10.1111/cod.13782
37. Zhang H, Xie Z. Symmetrical drug-related intertriginous and flexural exanthema induced by metronidazole suppository. Contact Dermatitis 2021; 84 (6): 486–8. DOI: 10.1111/cod.13780
38. Gulec AI, Uslu E, Başkan E et al. Baboon syndrome induced by ketoconazole. Cutan Ocul Toxicol 2014; 33 (4): 339–41. DOI: 10.3109/15569527.2013.870187
39. Kumar S, Bhale G, Brar BK. Symmetrical drug related intertriginous and flexural exanthema (SDRIFE) induced by fluconazole: An uncommon side effect of a commonly used drug. Dermatol Ther 2019; 32 (6): e13130. DOI: 10.1111/dth.13130
40. Mohapatra M, Panda M, Kar BR, Raj C. Symmetric Drug-related Intertriginous and Flexural Exanthema due to Itraconazole: An Uncommon Side Effect of a Commonly Used Drug. Indian Dermatol Online J 2017; 8 (6): 501–3. DOI: 10.4103/idoj.IDOJ_179_17
41. Hassanandani T, Panda M, Agarwal A, Das A. Rising trends of symmetrical drug related intertriginous and flexural exanthem due to Itraconazole in patients with superficial dermatophytosis: A case series of 12 patients from eastern part of India. Dermatol Ther 2020; 33 (6): e13911. DOI: 10.1111/dth.13911
42. Kalita BJ, Das S, Dutta B. Itraconazole-induced symmetrical drug-related intertriginous and flexural exanthema (SDRIFE): a rare occurrence. Int J Dermatol 2020; 59 (11): e419–e421. DOI: 10.1111/ijd.15049
43. Obara K, Maejima H, Katayama C et al. A case of symmetrical drug-related intertriginous and flexural exanthema induced by acetaminophen. J Dermatol 2014; 41 (12): 1132–3. DOI: 10.1111/1346-8138. 12666
44. Megna M, Cinelli E, Napolitano M et al. Paracetamol-induced symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) in a psoriasis patient receiving apremilast therapy. Contact Dermatitis 2019; 81 (6): 451–4. DOI: 10.1111/cod.13358
45. Lugović-Mihić L, Duvančić T, Vučić M et al. SDRIFE (baboon syndrome) due to paracetamol: case report. Acta Dermatovenerol Croat 2013; 21 (2): 113–7. URL:https://pubmed.ncbi.nlm.nih.gov/ 24001419/
46. Erfan G, Yanik ME, Kaya S et al. Symmetrical drug-related intertriginous and flexural exanthema due to codeine. Indian J Dermatol Venereol Leprol 2015; 81 (4): 405–6. DOI: 10.4103/0378-6323.158665
47. Martins JF, Alen Coutinho I, Castro M et al. Remifentanil-Induced Symmetric Drug-Related Intertriginous and Flexural Exanthema: A Diagnostic Challenge in an Intensive Care Patient. J Investig Allergol Clin Immunol 2022; 32 (5): 399–401. DOI: 10.18176/jiaci.0764
48. Weiss D, Kinaciyan T. Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) induced by mefenamic acid. JAAD Case Rep 2018; 5 (1): 89–90. DOI: 10.1016/j.jdcr.2018.10.015
49. Kim BJ, Kim HS, Lee JY et al. Symmetrical drug-related intertriginous and flexural exanthema caused by celecoxib. Int J Dermatol 2014; 53 (1): e1-3. DOI: 10.1111/j.1365-4632.2011.05243.x
50. Ding R, Cheo FF, Lee HY. Celecoxib and Bullous Symmetrical Drug-Related Intertriginous and Flexural Exanthem (SDRIFE). J Allergy Clin Immunol Pract 2023; 11 (2): 629–31. DOI: 10.1016/j.jaip. 2022.11.028
51. Caralli ME, Seoane Rodríguez M, Rojas Pérez-Ezquerra P et al. Symmetrical Drug-Related Intertriginous and Flexural Exanthema (SDRIFE) Caused by Etoricoxib. J Investig Allergol Clin Immunol 2016; 26 (2): 128–9. DOI: 10.18176/jiaci.0029
52. Watanabe T, Yamada N, Yoshida Y, Yamamoto O. A case of symmetrical drug-related intertriginous and flexural exanthema induced by loflazepate ethyl. J Eur Acad Dermatol Venereol 2010; 24 (3): 357–8. DOI: 10.1111/j.1468-3083.2009.03405.x
53. Suvarna P, Kayarkatte MN, Shenoi SD, Jaiprakash P. A rare case of clozapine-induced symmetrical drug-related intertriginous and flexural exanthema with vasculitis-like lesions. Contact Dermatitis 2020; 82 (5): 318–20. DOI: 10.1111/cod.13468
54. Rao A, Francis N, Morar N. Clozapine-induced symmetrical drug-related intertriginous and flexural exanthema: first reported cases. Br J Dermatol 2012; 166 (5): 1142–3. DOI: 10.1111/j.1365-2133.2011. 10758.x
55. Akkari H, Belhadjali H, Youssef M et al. Baboon syndrome induced by hydroxyzine.Indian J Dermatol 2013; 58 (3): 244. DOI: 10.4103/ 0019- 5154.110871
56. Allain-Veyrac G, Lebreton A, Collonnier C, Jolliet P. First case of symmetric drug-related intertriginous and flexural exanthema (SDRIFE) due to rivastigmine? Am J Clin Dermatol 2011; 12 (3): 210–3. DOI: 10.2165/11318350-000000000-00000
57. Akay BN, Sanli H. Symmetrical drug-related intertriginous and flexural exanthem due to oral risperidone. Pediatr Dermatol 2009; 26 (2): 214– 6. DOI: 10.1111/j.1525-1470.2009.00882.x
58. Treudler R, Simon JC. Symmetric, drug-related, intertriginous, and flexural exanthema in a patient with polyvalent intolerance to corticosteroids. J Allergy Clin Immunol 2006; 118 (4): 965–7. DOI: 10.1016/j.jaci.2006.07.023
59. Armingaud P, Martin L, Wierzbicka E, Esteve E. Baboon syndrome due to a polysensitization with corticosteroids. Ann Dermatol Venereol 2005; 132 (8–9 Pt. 1): 675–7. DOI: 10.1016/s0151-9638(05)79415-1
60. Garcia-Bravo B, Repiso JB, Camacho F. Systemic contact dermatitis due to deflazacort. Contact Dermatitis 2000; 43 (6): 359–60. DOI: 10.1034/j.1600-0536.2000.043006359.x
61. Virath R, Gupta LK, Balai M. A probable association of symmetrical drug-related intertriginous and flexural exanthema with levocetirizine. Indian J Dermatol Venereol Leprol 2020; 86 (6): 696–9. DOI: 10.4103/ijdvl.IJDVL_416_19
62. Yang SY, Lan CC, Hu SC. Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) induced by golimumab. Int J Dermatol 2017; 56 (5): 571–2. DOI: 10.1111/ijd.13565
63. Bulur I, Keseroglu HO, Saracoglu ZN, Gönül M. Symmetrical drug-related intertriginous and flexural exanthema (Baboon syndrome) associated with infliximab. J Dermatol Case Rep 2015; 9 (1): 12–4. DOI: 10.3315/jdcr.2015.1190
64. Keshavamurthy C, Fibeger E, Virata A, Bansal P. Symmetrical drug-related intertriginous and flexural exanthema (Baboon syndrome) associated with Infliximab: a case-based review. ARP Rheumatol 2022; 1 (4): 322–7. URL: https://pubmed.ncbi.nlm.nih.gov/36617314/
65. Göbel CH, Heinze A, Karstedt S et al. First Report of Symmetrical Drugrelated Intertriginous and Flexural Exanthema (SDRIFE or Baboon Syndrome) After Erenumab Application for Migraine Prevention. Pain Ther 2022; 11 (4): 1483–91. DOI: 10.1007/s40122-022-00417-6
66. Mofarrah R, Mofarrah R, Kränke B et al. First report of tamoxifen-induced baboon syndrome. J Cosmet Dermatol 2021; 20 (8): 2574–78. DOI: 10.1111/jocd.13863
67. Powers R, Gordon R, Roberts K, Kovach R. Symmetrical drug-related intertriginous and flexural exanthema secondary to topical 5-fluorouracil. Cutis 2012; 89 (5): 225-8. URL: https://pubmed.ncbi.nlm. nih.gov/22768435/#affiliation-1
68. Lewis W, Forrestel A, Baumrin E. Epidermal Growth Factor Receptor Inhibitor-Induced Symmetrical Drug-Related Intertriginous and Flexural Exanthema: Should You Discontinue the Offending Agent? Cutis 2023; 111 (1): 18–21. DOI: 10.12788/cutis.0681
69. Copps B, Lacroix JP, Sasseville D. Symmetrical drug-related intertriginous and flexural exanthema secondary to epidermal growth factor receptor inhibitor gefitinib. JAAD Case Rep 2020; 6 (3): 172–5. DOI: 10.1016/j.jdcr.2017.03.003
70. Keerty D, Graham L, Haynes E, Hembree TN. Flexural Exanthema From Enfortumab Vedotin. Cureus 2020; 12 (5): e8102. DOI: 10.7759/ cureus.8102
71. Malissen N, Bourrain J-L, Chiriac A et al. Symmetrical Intertriginous and Flexural Exanthema due to Bortezomib (a Proteasome Inhibitor) Given for Myeloma. Acta Derm Venereol 2016; 96: 995–6. DOI: 10.2340/00015555-241
72. Scherrer M, Araujo MG, Farah K. Tacrolimus-induced symmetric drugrelated intertriginous and flexural exanthema (SDRIFE). Contact Dermatitis 2018; 78 (6): 414–6. DOI: 10.1111/cod.12954
73. Kurtzman DJ, Oulton J, Erickson C, Curiel-Lewandrowski C. Everolimus-Induced Symmetrical Drug-Related Intertriginous and Flexural Exanthema (SDRIFE). Dermatitis 2016; 27 (2): 76–7. DOI: 10.1097/DER.0000000000000164
74. Ferreira O, Mota A, Morais P et al. Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) induced by telmisartan-hydrochlorothiazide. Cutan Ocul Toxicol 2010; 29 (4): 293–5. DOI: 10.3109/15569527.2010.491103
75. Tchernev G, Oliveira N, Kandathil LJ. Baboon syndrome (SDRIFE) after valsartan/hydrochlorothiazide intake for several years. Dermatol Reports 2021; 14 (2): 9412. DOI: 10.4081/dr.2022.9412
76. Kardaun SH, Tupker RA. Symmetrical drug-related intertriginous and flexural exanthema (Baboon syndrome) induced by omeprazole. Int J Dermatol 2012; 51 (9): 1134–7. DOI: 10.1111/j.1365-4632.2010.04689.x
77. Kothari R, Pal R, Bhatnagar A et al. A rare case of symmetrical drug-related intertriginous and flexural exanthema due to pantoprazole. Int J Dermatol 2022; 61 (9): e330–e331. DOI: 10.1111/ijd.16155
78. Spigariolo CB, Barei F, Maronese CA, Barberi F, Cattaneo A, Violetti SA. Three cases of symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) induced by proton-pump inhibitors. Australas J Dermatol 2022; 63 (4): 509–12. DOI: 10.1111/ajd.13905
79. Binitha MP, Sasidharanpillai S, John R, Sherjeena PV. Symmetrical drug-related intertriginous and flexural exanthema due to ranitidine. Indian J Pharmacol 2014; 46 (5): 551-2. DOI: 10.4103/0253- 7613.140595
80. Seok J, Kim JM, Park KY, Seo SJ. Symmetrical Drug-Related Intertriginous and Flexural Exanthema: Two Cases and Brief Literature Review. Ann Dermatol 2018; 30 (5): 606–9. DOI: 10.5021/ad.2018.30.5.606
81. Daito J, Hanada K, Katoh N et al. Symmetrical drug-related intertriginous and flexural exanthema caused by valacyclovir. Dermatology 2009; 218 (1): 60–2. DOI: 10.1159/000167829
82. Roche D, Murray G, Hackett C, Tobin AM. A flexural exanthem following postexposure prophylaxis. Clin Exp Dermatol 2022; 47 (6): 1204– 6. DOI: 10.1111/ced.15131
83. Heck J, Stichtenoth DO, Mettin R et al. Remdesivir-induced symmetrical drug-related intertriginous and flexural exanthema (SDRIFE)? A case report with review of the literature. Eur J Clin Pharmacol 2021; 77 (1): 141–4. DOI: 10.1007/s00228-020-02955-4
84. Çakıcı ÖA, Güder S, Salman A, Ergun T. Symmetrical drug-related intertriginous and flexural exanthema-like eruption: An addition to the spectrum of coronavirus disease 2019-related cutaneous findings. Indian J Dermatol Venereol Leprol 2022; 88 (6): 814–6. DOI: 10.25259/IJDVL_165_2022
85. Kandala H, Gonzalez-Mosquera LF, Barua P, Podrumar A. Zoledronic acid-induced symmetrical drug-related intertriginous and flexural exanthema (SDRIFE). BMJ Case Rep 2021; 14 (9): e245326. DOI: 10.1136/bcr-2021-245326
86. Cohen PR. Zoledronic acid-associated symmetrical drug-related intertriginous and flexural exanthema (SDRIFE): report of baboon syndrome in a woman with recurrent metastatic breast cancer after receiving zoledronic acid. Dermatol Online J 2015; 21 (8): 13030/qt5kk0g864. URL: https://pubmed.ncbi.nlm.nih.gov/26437156/
87. Cheng CY, Wang CW, Wang FY, Chung WH. Varenicline-induced symmetrical drug-related intertriginous and flexural exanthema. Indian J Dermatol Venereol Leprol 2019; 85 (2): 209–11. DOI: 10.4103/ijdvl.IJDVL_768_17
88. Thierman S, Chinthraja RS. Symmetrical drug-related intertriginous and flexural exanthema after coronary artery angiography. J Hosp Med 2009; 4 (3): 203. DOI: 10.1002/jhm.420
89. Arnold AW, Hausermann P, Bach S, Bircher AJ. Recurrent flexural exanthema (SDRIFE or baboon syndrome) after administration of two different iodinated radio contrast media. Dermatology 2007; 214 (1): 89–93. DOI: 10.1159/000096920
90. Hattori Y, Matsuyama K, Shu E et al. Symmetrical drug-related intertriginous and flexural exanthema possibly due to thiamine disulfide. J Dermatol 2017; 44 (6): e115-e116. DOI: 10.1111/1346-8138.13776
91. Peeters D, Baeck M, Dewulf V et al. A case of SDRIFE induced by Nuvaring®. Contact Dermatitis 2012; 66 (2): 110–1. DOI: 10.1111/j.1600- 0536.2011.01990.x
92. Matos-Pires E, Pina-Trincão D, Brás S, Lobo L. Baboon syndrome caused by anti-haemorrhoidal ointment. Contact Dermatitis 2018; 78 (2): 170–1. DOI: 10.1111/cod.12880
93. Liu J, Li LF. Symmetrical drug-related intertriginous and flexural exanthema/baboon syndrome induced by traditional Chinese medicine. J Cosmet Dermatol 2022; 21 (5): 2200–4. DOI: 10.1111/jocd. 14343
94. Choi MJ, Oh SH, Cho SB. Coix lacryma-jobi associated symmetrical drug-related intertriginous and flexural exanthema. Int J Dermatol 2014; 53 (4): e301-3. DOI: 10.1111/ijd.12258
95. Labadie JG, Florek AG, Croitoru A et al. First case of symmetrical drugrelated intertriginous and flexural exanthema (SDRIFE) due to Berberine, an over-the-counter herbal glycemic control agent. Int J Dermatol 2018; 57 (9): e68-e70. DOI: 10.1111/ijd.14059
96. Chen B, Jiang X, Chen W et al. A rare case of musk antihemorrhoids ointment-induced symmetrical drug-related intertriginous and flexural exanthema. Contact Dermatitis 2020; 83 (5): 409–11. DOI: 10.1111/cod.1357
97. Mahé A, Birckel E, Krieger S et al. A distinctive skin rash associated with coronavirus disease 2019? J Eur Acad Dermatol Venereol 2020; 34 (6): e246–e247. DOI: 10.1111/jdv.16471
98. Escolà H, March-Rodriguez A, Pujol RM. Symmetrical drug-related intertriginous and flexural exanthema-like rash related to severe acute respiratory syndrome coronavirus 2 infection. Indian J Dermatol Venereol Leprol 2023; 89 (1): 119–21. DOI: 10.25259/IJDVL_355_2022
99. Chicharro P, Rodríguez-Jiménez P, Muñoz-Aceituno E et al. SDRIFElike rash associated with COVID-19, clinicopathological correlation. Australas J Dermatol 2021; 62: 88–9. DOI: 10.1111/ajd.13444
100. Bonamigo RR, Bottega GB, Staub FL et al. Bullous SDRIFE and Covid19. Int J Dermatol 2022; 6: 372–4. DOI: 10.1111/ijd.16012
101. Bevilaqua M, Ribolli GB, Luzzatto L et al. SDRIFE-like rash in COVID19 patient: drug reaction or another cutaneous manifestation of SARSCoV-2? Int J Dermatol 2021; 60: 884–5. DOI: 10.1111/ijd.15537
102. Bellinato F, Maurelli M, Gisondi P, Girolomoni G. Cutaneous Adverse Reactions Associated with SARS-CoV-2 Vaccines. J Clin Med 2021; 10 (22): 5344. DOI: 10.3390/jcm10225344
103. Manaa A, Ziv M, Krausz J, Dodiuk-Gad RP. A case of symmetrical drug-related intertriginous and flexural exanthema-like eruption associated with Pfizer COVID-19 vaccination. Dermatol Ther 2022; 35 (7): e15546. DOI: 10.1111/dth.15546
104. Lahouel I, Ben Salah N, Ben Fadhel N et al. Symmetrical drug-related intertriginous and flexural exanthema-like eruption after COVID-19 vaccine. J Eur Acad Dermatol Venereol 2022; 36 (8): e597–e599. DOI: 10.1111/jdv.18108
105. Hai J, Shawa H, Kim-Lim P et al. Systemic drug-related intertriginous and flexural exanthema induced by the Pfizer-BioNTech COVID-19 vaccine: A report of 2 cases. JAAD Case Rep 2021; 18: 57–60. DOI: 10.1016/j.jdcr.2021.10.016
106. Hong JK, Shin SH, Yoo KH et al. Symmetric drug-related intertriginous and flexural exanthema-like eruption related to coronavirus disease 2019 vaccine. Contact Dermatitis 2022; 87 (1): 91–3. DOI: 10.1111/cod.14092
107. Lim PN, Wylie G. Symmetrical drug-related intertriginous and flexural exanthema like eruption associated with COVID-19 vaccination. Clin Exp Dermatol 2022; 47 (1): 175–6. DOI: 10.1111/ced.14898
108. Di Bona D, Miniello A, Nettis E. Systemic drug-related intertriginous and flexural exanthema-like eruption after Oxford-AstraZeneca COVID-19 vaccine. Clin Mol Allergy 2022; 20 (1): 13. DOI: 10.1186/s12948-022-00179-8
109. Orenay OM, Balta I, Yigit D, Eksioglu M. Systemic drug-related intertriginous and flexural exanthema like eruption after CoronaVac vaccine. J Eur Acad Dermatol Venereol 2021; 35 (10): e634-e635. DOI: 10.1111/jdv.17454
110. Pottegård A, Hallas J, Olesen M et. al. Hydrochlorothiazide use is strongly associated with risk of lip cancer. J Intern Med 2017; 282 (4): 322–31. DOI: 10.1111/joim.12629
111. Pedersen SA, Gaist D, Schmidt SAJ et al. Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark. J Am Acad Dermatol 2018; 78 (4): 673–81.e9. DOI: 10.1016/j.jaad.2017.11.042
112. Garrido PM, Borges-Costa J. Hydrochlorothiazide treatment and risk of non-melanoma skin cancer: Review of the literature. Rev Port Cardiol (Engl Ed) 2020; 39 (3): 163–70. DOI: 10.1016/j.repc.2019. 07.008
113. Lecaros-Astorga DA, Molina-Guarneros JA, Rodríguez-Jiménez P et al. Hydrochlorothiazide use and risk of non-melanoma skin cancer in Spain: A case/non-case study. Int J Clin Pharmacol Ther 2021; 59 (4): 280–8. DOI: 10.5414/CP203769
114. Becquart O, Guillot B, Bourrain J-L et al. Hydrochlorothiazide use and risk of skin cancers: A systematic review. Rev Med Interne 2019; 40 (9): 617–22. DOI: 10.1016/j.revmed.2019.04.008
114. Letellier T, Le Borgne F, Kerleau C et al; Divat Consortium. Association between Use of Hydrochlorothiazide and Risk of Keratinocyte Cancers in Kidney Transplant Recipients. Clin J Am Soc Nephrol 2020; 15 (12): 1804–13. DOI: 10.2215/CJN.02560220
115. Carney K, Cousins M. Does hydrochlorothiazide increase the incidence of skin, lip and oral cancer in a UK population? Evid Based Dent 2022; 23 (1): 38–9. DOI: 10.1038/s41432-022-0255-x
116. Eworuke E, Haug N, Bradley M et al. Risk of Nonmelanoma Skin Cancer in Association With Use of Hydrochlorothiazide-Containing Products in the United States. JNCI Cancer Spectr 2021; 5 (2): pkab009. DOI: 10.1093/jncics/pkab009
116. Rouette J, Yin H, Pottegård A et.al. Use of Hydrochlorothiazide and Risk of Melanoma and Nonmelanoma Skin Cancer. Drug Saf 2021; 44 (2): 245–54. DOI: 10.1007/s40264-020-01015-1
117. de Macedo Andrade AC, Felix FA, França GM et al. Hydrochlorothiazide use is associated with the risk of cutaneous and lip squamous cell carcinoma: A systematic review and meta-analysis. Eur J Clin Pharmacol 2022; 78 (6): 919–30. DOI: 10.1007/s00228-022-03299-x
118. Shao SC, Lai CC, Chen YH et al. Associations of thiazide use with skin cancers: a systematic review and meta-analysis. BMC Med 2022; 20 (1): 228. DOI: 10.1186/s12916-022-02419-9
119. Habel LA, Achacoso N, Fireman B et.al. Hydrochlorothiazide and risk of melanoma subtypes. Pharmacoepidemiol Drug Saf 2021; 30 (10): 1396–401. DOI: 10.1002/pds.5266
120. Adalsteinsson JA, Muzumdar S, Waldman R et al. Association between hydrochlorothiazide and the risk of in situ and invasive squamous cell skin carcinoma and basal cell carcinoma: A population-based casecontrol study. J Am Acad Dermatol 2021; 84 (3): 669–75. DOI: 10.1016/j.jaad.2020.08.025
Для цитирования:Трухан Д.И. Синдром бабуина или симметричная интертригинальная и изгибная экзантема, связанная с лекарственными средствами. Обзор клинических случаев. Клинический разбор в общей медицине. 2023; 4 (5): 63–70. DOI: 10.47407/kr2023.4.5.00236
Журнал предоставляет свободный доступ с возможностью использовать статьи в некоммерческих целях при условии указания авторства в рамках лицензии CC BY-NC-SA 4.0 (https://creativecommons.org/licenses/by-nc-sa/4.0/deed.ru)
